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Biomarker discovery has an accelerated pace is taking advan-
tage of ever growing omics technologies. In the last years
we are facing the development of a myriad of technologies
searching for the “golden biomarker.” The omics family
is constantly adding a new member, such as genomics,
proteomics, peptidomics, newer ones, epigenomics, tran-
scriptomics, metabolomics, lipidomics, pharmacogenomics,
interactomics, and chronemics, just mentioning a few [1].
In the biomarker development, approaches are multidis-
ciplinary, from basic to translational and clinical research. As
biological processes are complex, for example, tumorigenesis,
multitechnological approaches are crucial for protein/gene
biomarkers discovery. Biomarker discovery goes through
laborious individual phases, such as biomarker candidate
identification, verification, and validation. In all these phases,
various omics technologies take the lead. Depending on
the development stage, when characterizing thousands to
tens of thousands of proteins, the key technological play-
ers are mass spectrometry, multiplexed assays, and protein
microarrays. For genomic studies, technological platforms
of gene microarrays, next-generation sequencing, and mass
spectrometry generate tumor-associated genes and potential
biomarkers. Complementary omics approaches intended for
biomarker candidates selection should focus on multiple
proteomic/genomic/metabolomic targets.Thesemultifaceted
targets could better explain complex disease mechanisms [2].
The special issue is governed by three tumor patholo-
gies, skin cancer, lung cancer, and colorectal cancer, while
precancerous lesions like ulcerative colitis or particular
inflammatory conditions like keratoconus, kidney disease, or
microRNAs in pathological pregnancy are also tackled.
Hence from the large group of skin cancers papers, M.
Lupu et al. review the genomic and the proteomic profile
of basal cell carcinoma, the world’s leading skin cancer.
The paper analyzes the gene expression and proteomic
profiling of both tumor cells and tumoral microenvironment.
These patterns can represent novel predictive and prognostic
biomarkers in BCC.
The secondmost frequent skin cancer squamous cells car-
cinoma is reviewed byV.Voiculescu et al. where environmen-
tal factor ultraviolet light, chronic scarring/inflammation,
exposure to chemical compounds, and immune suppression
can favour tumorigenesis. The paper shows that malig-
nant keratinocyte proteome analysis is the pool for novel
biomarker discovery future to be used in early detection, risk
assessment, tumor monitoring, and development of targeted
therapeutic strategies.
Another skin related paper focuses on melanoma devel-
opment andG. Turcu et al. revised an interesting newpossible
biomarker, carcinoembryonic antigen cell adhesionmolecule
1 (CEACAM1) with a definite role in melanoma metastasis.
Knowing that melanoma progression is associated with cell
adhesion molecules dysregulation, this molecule can further
stratify high risk patients identifying subgroups that require
close follow-up or more aggressive therapy.
Lung cancer was approached in two papers of this
special issue. A. Quintanal-Villalonga et al. reviewed tyrosine
kinase receptor with its therapeutical implications in lung
cancer showing that in the “omics” landscape tyrosine kinase
receptors gained their role in the different histological types
of lung cancer. This receptor is highly involved in specific
antitumoral therapies.
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In the same field of lung cancer, A. Marrugal et al.
reviewed the cytokines pattern due to their involvement
in the inflammatory processes that can trigger and sustain
tumorigenesis. Different proteomic techniques are presented
in the continuous quest for biomarkers discovery in lung
cancer. Within the future biomarker candidates, several
cytokines are presented as important players in lung cancer
that can stand for future therapy targets.
Colorectal cancer was another important subject pre-
sented in this special issue where J. Wei et al. presented
their findings regarding hypermethylatedmarkers.They have
mapped DNA methylation profiling in colorectal cancer tis-
sues. Over 1500 differentially methylated regions were found
that proved to be different in colorectal cancer compared to
normal tissue. Among these differentially methylated regions
two genes (ADD2 and AKR1B1) are presented as potential
screening markers of colorectal cancer.
Another original research paper within this issue is
the one presented by C. Popp et al. regarding the specific
expression profile of p53 and p21 in large bowel mucosa.
The expression of p53 and p21 can be considered biomarker
of inflammatory-related carcinogenesis in ulcerative colitis
as a disease that slightly increases the risk of colorectal
cancer in patients. The paper presents a one-year prospective
observational study that shows results for future use of p53
as the most valuable tissue biomarker in ulcerative colitis
surveillance, identifying higher risk for dysplasia patients.
Similarly, in the paper of C. Ionescu et al., inflamma-
tory biomarkers for keratoconus are revised. Keratoconus,
a degenerative disorder, results in decreased vision and
irreversible tissue scarring and still has an unclear pathogen-
esis. Combination of inflammatory patterns and genetic and
environmental factors are incriminated and studied in this
type of special pathology. This paper revises biomarkers of
inflammation and their signaling pathways that can indicate
the etiopathogeny of this disease and that furnish new
therapeutic possibilities.
Another pathology, chronic kidney disease-related bio-
markers are presented by the original work of S. Mihai
et al. Within the paper a panel of proteomic biomarkers,
comprising inflammation markers (IL-6 and TNF-𝛼) and
mineral and bone disorder biomarkers (OPG, OPN, OCN,
FGF-23, and Fetuin-A), was found to detect early chronic
kidney disease.
Although a normal physiological condition, pregnancy
can have a wide range of pathological conditions. D. Cretoiu
et al. revise circulating microRNAs as potential biomarkers
in pregnancy and show the significance of these circulat-
ing molecular markers from the implantation period to
preeclampsia and their involvement in pathological processes
like recurrent abortion and ectopic pregnancy.
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